课件：全球仿制药市场--上海.ppt

* * 2 2 Check when reforms where introduced (Russia, Turkey) In Brazil, key reasons for continued growth: Better income distribution; Growing GDP; Better distribution systems by NTL; aging population. Proportion of population above 60 years in Brazil, which was around 8% in 2000 will almost double in 2020. Brazil holds good healthcare indicators compared to other BRIC members. Large portion of the economic growth can be described by the improvement in the wealth distribution * 全球 美国 欧盟5国 日本 1级新兴药品市场 2级新兴药品市场 3级新兴药品市场 美国 日本 德国 法国 意大利 加拿大 西班牙 英国 成熟市场 Teva Value sales market share Pharmerging 6% 8 Established 79% RUSSIA 36% VENEZUELA 21% POLAND 19% ARGENTINA 13% ROMANIA 4% TURKEY 3% MEXICO 1% CHINA 1% THAILAND 1% S. AFRICA 1% INDONESIA 1% VIETNAM 0% PAKISTAN 0% BRAZIL 0% EGYPT 0% * * * * * Claire Machin March 2011 Patent Cliff Info Value of patent cliff for products with patent expiries (Q3+4 only for 2011) 2011-2015 = $160Bn (Market Seg countries only) Top 10 products losing protection (Q3+4 only for 2011) 2011-2015 and their market share of $160Bn from above LIPITOR 7% SERETIDE 5% PLAVIX 5% NEXIUM 4% SEROQUEL 4% ABILIFY 4% YPREXA 3% SINGULAIR 3% CYMBALTA 3% ACTOS 2% USA Negative OB volume growth Forecasted at -1.5% in 2011 but will recover to produce a growth of 1.5% in 2013 EU5 Improving access to drugs in France A new national plan for rare diseases (Plan National Maladies Rares, PNMR), covering the years 2011-2014, has been presented by the government. Total funding of €180 million has been allocated to the plan, which aims to improve diagnosis and treatment, promote research into rare diseases and encourage greater European/international collaboration (by sharing expertise etc). Included in the key measures are two initiatives to improve access to drugs. The government will simplify the procedure for obtaining reimbursement approval for drugs used outside of their a